ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 916,08
-0,93%
Dow Jones
41 583,90
-1,69%
DAX
22 461,52
-0,89%
Brent Oil
72,475
0,00%
Bitcoin
82 770,06
-1,87%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allakos Inc (ALLK)

  7. Allakos Inc (ALLK) Actualités

ALLK

Allakos (ALLK)

Allakos Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALLK
DateHeureSourceTitreSymboleSociété
13/03/202521h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
12/03/202521h11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALLKAllakos Inc
12/03/202521h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial ResultsNASDAQ:ALLKAllakos Inc
07/03/202523h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
06/03/202522h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
27/01/202513h00GlobeNewswire Inc.Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces RestructuringNASDAQ:ALLKAllakos Inc
13/01/202522h07Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALLKAllakos Inc
19/12/202422h15PR Newswire (US)Kuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmNASDAQ:ALLKAllakos Inc
06/11/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLKAllakos Inc
10/10/202422h02GlobeNewswire Inc.Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersNASDAQ:ALLKAllakos Inc
07/08/202422h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:ALLKAllakos Inc
25/06/202422h02GlobeNewswire Inc.Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety ProfileNASDAQ:ALLKAllakos Inc
28/05/202413h02GlobeNewswire Inc.Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaNASDAQ:ALLKAllakos Inc
09/05/202422h02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:ALLKAllakos Inc
14/03/202421h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
26/02/202413h02GlobeNewswire Inc.Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024NASDAQ:ALLKAllakos Inc
17/02/202401h08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
14/02/202422h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
12/02/202413h02GlobeNewswire Inc.Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
02/02/202418h31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALLKAllakos Inc
26/01/202422h20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALLKAllakos Inc
16/01/202413h02GlobeNewswire Inc.Allakos Announces a Restructuring to Focus on Development of AK006NASDAQ:ALLKAllakos Inc
16/01/202413h00GlobeNewswire Inc.Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsNASDAQ:ALLKAllakos Inc
27/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLKAllakos Inc
13/11/202323h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLKAllakos Inc
13/11/202322h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
30/08/202322h05GlobeNewswire Inc.Allakos Appoints Neil Graham to its Board of DirectorsNASDAQ:ALLKAllakos Inc
09/08/202322h02GlobeNewswire Inc.Allakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
02/08/202322h05GlobeNewswire Inc.Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of DirectorsNASDAQ:ALLKAllakos Inc
12/06/202313h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALLKAllakos Inc
 Showing the most relevant articles for your search:NASDAQ:ALLK

Dernières Valeurs Consultées

NYSE
ITGR
Integer
AMEX
BBUS
JPMorgan BetaBuilders US...
AMEX
BOIL
ProShares Ultra Bloomber...
NYSE
NXDT
NexPoint Diversified Rea...
NASDAQ
EXE
Expand Energy
AMEX
IPOS
Renaissance Internationa...
AMEX
OILK
ProShares K 1 Free Crude...
AMEX
DBJP
Xtrackers MSCI Japan Hed...
NASDAQ
WWD
Woodward
AMEX
PAVE
Global X US Infrastructu...
NASDAQ
SPC
CrossingBridge Pre Merge...
USOTC
AGSS
AmeriGuard Security Serv... (QX)
NASDAQ
FLL
Full House Resorts
NYSE
ORCL
Oracle
BOV
S1PL34Q
Splunk
AQSE
VJPN.GB
Vanguard Ftse Japan Ucit...
Delayed Upgrade Clock
ADVFN Logo
France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces